Why Cancer Drugs Are At The Centre Of The Hospital Stocks Debate

In this episode of Markets Today, we decode 3 big stories — a Supreme Court case on cancer drug mark-ups hammering hospital stocks, what NSE's IPO retail response signals for the Jio Platforms IPO, and three numbers setting the stage for Q2 earnings season.

Cancer Drug Mark-Ups & Hospital Stocks Supreme Court asked if the 16% trade margin on scheduled drugs extends to non-scheduled drugs — 82% of all medicines. Hospital stocks down 8-12% since September 22. Next hearing: October 12.

NSE IPO's Read-Through For Jio's ₹37,700 Crore Issue NSE subscribed 5.71x overall but only 1.39x by retail, listing at just 0.84% premium. Jio's issue is structurally different — fresh shares, proceeds largely used to prepay borrowings.

Three Numbers Shaping Q2 Earnings GDP at 7.8%, rainfall at 87% of normal, crude crossing $100. Cement, autos, banks and IT will each read them very differently.